Published in Cancer Manag Res on October 27, 2010
Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer. PLoS One (2011) 0.93
miRGate: a curated database of human, mouse and rat miRNA-mRNA targets. Database (Oxford) (2015) 0.88
Epigenetic research in cancer epidemiology: trends, opportunities, and challenges. Cancer Epidemiol Biomarkers Prev (2013) 0.78
Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma. Clin Epigenetics (2016) 0.76
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
A haplotype map of the human genome. Nature (2005) 105.70
The sequence of the human genome. Science (2001) 101.55
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
The functions of animal microRNAs. Nature (2004) 64.85
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
The diploid genome sequence of an Asian individual. Nature (2008) 46.29
The language of covalent histone modifications. Nature (2000) 44.92
The diploid genome sequence of an individual human. PLoS Biol (2007) 44.80
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
The epigenomics of cancer. Cell (2007) 30.91
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
Real-time DNA sequencing from single polymerase molecules. Science (2008) 29.53
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science (2009) 21.24
The impact of next-generation sequencing technology on genetics. Trends Genet (2008) 21.07
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Epigenetics in cancer. N Engl J Med (2008) 17.36
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
The potential and challenges of nanopore sequencing. Nat Biotechnol (2008) 14.24
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet (2009) 13.12
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
The DNA methyltransferases of mammals. Hum Mol Genet (2000) 10.66
Cellular differentiation, cytidine analogs and DNA methylation. Cell (1980) 10.15
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet (2007) 9.88
Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat Methods (2010) 9.75
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 9.28
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med (2004) 6.91
Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues. Nucleic Acids Res (1980) 5.03
Tuning gene expression to changing environments: from rapid responses to evolutionary adaptation. Nat Rev Genet (2008) 3.84
High-throughput DNA sequencing--concepts and limitations. Bioessays (2010) 3.77
CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res (1999) 3.66
An elaborate pathway required for Ras-mediated epigenetic silencing. Nature (2007) 3.47
DNA methylation, methyltransferases, and cancer. Oncogene (2001) 3.30
Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet (2007) 3.12
HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med (2008) 3.05
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94
Altering gene expression with 5-azacytidine. Cell (1985) 2.79
DNA methylation: a profile of methods and applications. Biotechniques (2002) 2.74
The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A (1996) 2.63
Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res (2005) 2.57
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol (2007) 2.48
Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene (2002) 2.27
The emerging science of epigenomics. Hum Mol Genet (2006) 2.22
DNA methylation as a therapeutic target in cancer. Clin Cancer Res (2007) 2.20
Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle (2006) 1.98
Relevance of DNA methylation in the management of cancer. Lancet Oncol (2003) 1.97
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood (2009) 1.86
Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene (2008) 1.78
The regulation of direct-to-consumer genetic tests. Hum Mol Genet (2008) 1.77
Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev (2008) 1.74
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol (2008) 1.72
Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res (2002) 1.71
The microRNA network and tumor metastasis. Oncogene (2009) 1.71
Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology (2008) 1.66
Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol (2006) 1.59
ChIP-chip comes of age for genome-wide functional analysis. Cancer Res (2006) 1.55
Molecular therapy in the microRNA era. Pharmacogenomics J (2006) 1.52
5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia (1993) 1.48
Vorinostat in solid and hematologic malignancies. J Hematol Oncol (2009) 1.42
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther (2010) 1.34
Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood (2010) 1.26
Nanopore sequencing technology: research trends and applications. Trends Biotechnol (2006) 1.24
Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. Epigenomics (2009) 1.22
Epigenomic profiling using microarrays. Biotechniques (2003) 1.21
Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res (1983) 1.19
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol (2010) 1.14
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol (2008) 1.14
Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma (2007) 1.13
Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Cancer (2007) 1.11
The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol (2008) 1.10
Sirtuin inhibitors. Expert Opin Ther Pat (2009) 1.05
Human genome at ten: Science after the sequence. Nature (2010) 1.02
Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene (2004) 1.02
c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One (2010) 1.01
Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol (2009) 1.00
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci U S A (2010) 0.99
ADAM23 negatively modulates alpha(v)beta(3) integrin activation during metastasis. Cancer Res (2009) 0.98
SATR-1 hypomethylation is a common and early event in breast cancer. Cancer Genet Cytogenet (2006) 0.96
The impact of microRNAs and alternative splicing in pharmacogenomics. Pharmacogenomics J (2009) 0.96
Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2'-deoxycytidine results in increased tumorigenicity. PLoS One (2009) 0.95
Methylation-sensitive representational difference analysis and its application to cancer research. Ann N Y Acad Sci (2003) 0.94
S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther (2010) 0.94
ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer (2009) 0.93
Modular paths to 'decoding' and 'wiping' histone lysine methylation. Curr Opin Chem Biol (2007) 0.91
"Promoter array" studies identify cohorts of genes directly regulated by methylation, copy number change, or transcription factor binding in human cancer cells. Ann N Y Acad Sci (2005) 0.91
Toward nanoscale genome sequencing. Trends Biotechnol (2007) 0.89